DOCSLIB.ORG

Immunoprophylaxis of Influenza Using AAV Vector Delivery of Cross

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Immunoprophylaxis of Influenza using AAV Vector Delivery of Cross-Subtype Neutralizing Single Domain Antibodies JOANNE MARIE M. DEL ROSARIO Thesis submitted for the degree of Doctor of Philosophy Infection and Immunity University College London 2020 To Chris, as fate would have it. To Teki, thank you for everything. 2 DECLARATION I, Joanne Marie M. Del Rosario, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. __________________________ 3 ABSTRACT Cross-subtype neutralizing single domain antibodies against influenza present new opportunities for immunoprophylaxis and pandemic preparedness. Their simple modular structure and single open reading frame format are highly amenable to gene therapy-mediated delivery. R1a-B6, an alpaca-derived single domain antibody (nanobody), that is capable of potent cross-subtype neutralization in vitro of H1N1, H5N1, H2N2, and H9N2 influenza viruses, through binding to a highly conserved epitope in the influenza hemagglutinin stem region, was previously described. To evaluate the potential of R1a-B6 for immunoprophylaxis via adeno-associated viral (AAV) vector delivery, it was reformatted as Fc fusions of mouse IgG1 (ADCC-) and IgG2a (ADCC+) isotypes. This is also to extend R1a-B6’s half-life and to assess the requirement for ADCC for efficacy of R1a-B6 in vitro and in vivo. It was found that reformatted R1a-B6 of either mouse IgG isotype retained its potent binding and neutralization activity against different Group I influenza A subtypes in vitro. The findings in this study also demonstrate that a single intramuscular injection in mice of AAV encoding R1a-B6-Fc was able to drive sustained high-level expression (0.5–1.1 mg/mL) of the nanobody-Fc in sera with no evidence of reduction for up to 6 months. R1a-B6-Fc fusions of both isotypes gave complete protection against lethal challenge with both pandemic A/California/07/2009 (H1N1)pdm09 and mouse-adapted avian influenza A/Vietnam/1194/2004 (H5N1). These data suggest that R1a-B6-Fc delivered via AAV is capable of cross-subtype protection and ADCC was not essential for protection. These findings reveal that AAV delivery of cross-subtype neutralizing nanobodies may be an effective strategy to prevent influenza infection and provide long-term protection independent of a host induced immune response. 4 IMPACT STATEMENT Although vaccines are the main countermeasure against pandemic influenza, their timely implementation and ineffectiveness in vulnerable patient groups present challenges. We need a pro-active and pre-emptive approach in tackling influenza especially in the case of a pandemic emergency. Novel interventions using broadly neutralizing monoclonal antibodies (mAbs) are under clinical development, however their structural complexity, expensive production and requirement for repeated injections are limitations to widespread use. Adeno associated virus (AAV) vectors were used to deliver a much simpler broadly neutralizing single domain antibody (nanobody R1a-B6) specific for a highly conserved epitope in the influenza hemagglutinin stem region. A one-time intramuscular delivery route aiming for longer expression and stricter dosing control in preference to intranasal delivery that may be obstructed due to congestion and a reflex sniffing response of the recipient leading to reduced efficacy of delivery was evaluated. Findings demonstrate high level, long- term expression in vivo, which protected mice from lethal challenge by both pandemic H1N1 and highly pathogenic avian influenza H5N1. Surprisingly, Fc-mediated antibody dependent cellular cytotoxicity (ADCC) was not essential for R1a-B6 efficacy when expressed at high levels in vivo which contrasts with that described previously for similar stem binding human mAbs when injected as purified protein. These findings have implications in developing the optimum antibody format and delivery option to provide safe, long-term protection, independent of the patient’s immune response and prior exposure to influenza, that can be utilized in the instance of a pandemic. 5 ACKNOWLEDGEMENTS I would like to extend my gratitude to the following people who have made this PhD a unique and positive learning experience. The support of these amazing people has been vital in the most challenging and humbling of times. My supervisors, Dr. Yasuhiro Takeuchi and Dr. Simon Hufton, for really taking on the job and teaching, correcting, and guiding me every step of the way. I finish this PhD, hopefully a better scientist, and definitely a better person, than I was before, because of your training, encouragement, patience, kindness and friendship. I have been very blessed to have you as my advisers. The DPSM faculty and team, and the Chemistry unit of the University of the Philippines Manila for their unwavering support from start to finish of my PhD. None of this would have been possible without you. Professor Mary Collins for helpful insight and advice. I would not have been here if you and Yasu did not take a chance on me. Professor Paul Digard and Dr. Laura McCoy, whose extensive examination have helped make this piece of work better. I have learned so much in those 4 hours. Dr. Matthew Smith for all the exciting influenza work that you taught me. It has been a pleasure sharing the bench with such an awesome scientist like you. Christina Ball, Paul Risley, Dr. Kam Zaki and Dr. Ilaria Nisoli for sharing your expertise and time with me. Dr. Othmar Engelhardt and Dr. Nigel Temperton for being supportive and critical collaborators, who have enriched this body of work. Rose, Alan, Shaun, Christine, Vicky and all the wonderful people in the Biological Services Division at NIBSC for going over and beyond to help me with the animal work. Our colleagues at the Biotherapeutics Division and the Influenza Resource Center at NIBSC for help and advice with this project. 6 My former students, for always cheering me on. Your belief in me has made me become more of what I already am. The friends that I have made here in London especially Bea, Jasmine and Pedro, and Chris’s family who have made being in another country an incredibly fun, uplifting and a most rewarding experience. And all my friends back in the Philippines and scattered all around the world who have always cheered me on and believed in me even at times when I doubt myself. Gabby, Ciara, Andrea (x2) and Diana, for listening to all my ranting, and for always calming me down when things don’t go as planned. Jules, Kevin, Dem, Jireh and Hermie, eternal friends, rambunctious supporters, together we are untouchable. Arlou, it is finally done! And I share this victory with you, one of many in our bright future. Tom, Ryan and Martin, NIBSC became home because you were there. Work did not feel like work, and we fostered a happy, productive, supportive environment, that I would always cherish. Teki, for being my rock. I have borrowed from your strength so much and you have kept me standing through the best and worst of it. My family and my Bicho for your unconditional love and faith in me. Being away from you has not been easy but I thank you for sharing my dreams and helping me in making them happen, and always, always, praying for me. This is the product of all our sacrifices. Chris, my clever boy, for all the late nights, stimulating discussions and inspiring banter. For suffering and rejoicing with me and holding my hand through our inflatable bed journey. Everything will be worth it in the end. Smart ka talaga for sharing this incredible adventure with me. And finally, infinite thanks to HIM, the Giver of all good things. 7 TABLE OF CONTENTS DECLARATION . 3 ABSTRACT . 4 IMPACT STATEMENT . 5 ACKNOWLEDGEMENTS . 6 TABLE OF CONTENTS . 8 LIST OF FIGURES . 12 LIST OF TABLES . 14 ABBREVIATIONS . 15 CHAPTER 1. INTRODUCTION . 19 1.1 Thesis Overview . 19 1.2 Influenza . 19 1.2.1 Influenza A Biology . 19 1.2.2 Replication cycle . 22 1.2.3 Pathogenesis . 24 1.2.4 Burden and Epidemiology . 27 1.2.5 Pandemic threats . 29 1.2.6 Prevention and Treatment . 31 1.3 Innate Immune Response to Influenza . 37 1.4 Antibody Immune Response to Influenza . 38 1.5 Passive Immunotherapy against Influenza . 42 1.5.1 Broadly neutralizing Antibodies (bnAb) . 44 1.5.2 Nanobodies (Nb) . 48 1.5.2.1 Nanobody Re-Formatting to increase Half-Life . 52 1.5.2.2 Nanobodies with Effector functions . 56 1.5.2.3 Nanobodies against Influenza . 59 1.6 Gene Therapy and Viral Vectors . 62 1.6.1 Recombinant Adeno-Associated Virus (rAAV) . 64 1.6.2 rAAV in clinical trials . 68 1.6.3 rAAV and influenza . 71 8 1.7 Universal Influenza Vaccine . 73 1.8 Thesis Objectives . 75 CHAPTER 2. MATERIALS AND METHODS . 77 2.1 General . 77 2.1.1 Propagation and maintenance of cell cultures . 77 2.1.1.1 ExpiCHO-S™ cells . 77 2.1.1.2 Human embryonic kidney (HEK) 293T cells . 77 2.1.1.3 Madin-Darby canine kidney (MDCK) cells . 77 2.1.2 Restriction Digestion . 77 2.1.3 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis . 78 2.1.4 Western Blotting . 79 2.1.5 Enzyme-Linked Immunosorbent Assay (ELISA) . 79 2.1.6 Statistical Analysis . 80 2.2 Production and purification of nanobody-Fc fusion proteins . 80 2.2.1 Cloning of nanobody-Fc in mammalian expression vector . 80 2.2.2 Transfection in ExpiCHO-S™ cells . 81 2.2.3 Protein A Affinity Chromatography . 82 2.2.4 Dialysis . 82 2.3 In vitro assays for nanobody-Fc specificity and neutralization activity . 83 2.3.1 Influenza ELISA panel . 83 2.3.2 Antibody Dependent Cell Cytotoxicity (ADCC) reporter assay .
Recommended publications
  • Spotlight on Market Access Actionable Understandings from AIS Health’S In-Depth Coverage

    Spotlight on Market Access Actionable Understandings from AIS Health’S In-Depth Coverage

    Spotlight on Market Access Actionable understandings from AIS Health’s in-depth coverage September 16, 2019 Recent Situations Stress That Data Is More Important Than Ever to FDA, Drug Uptake 2 Clinical Trials by Indication: Q2 2019 A pair of drugmakers and the FDA found themselves in the news lately, but it’s safe to say it wasn’t for the reasons they would prefer. Both situations Reality Check: PCSK9 Inhibitors 8 stress the importance of data needed to secure product approvals, and, per- haps, payer and provider uptake. On Aug. 6, the FDA put out a statement addressing “data accuracy issues” with Zolgensma (onasemnogene abeparvovec-xioi), a new gene ther- apy to treat spinal muscular atrophy in people less than 2 years old who have bi-allelic mutations in the survival motor neuron 1 gene, including those who are presymptomatic when diagnosed. The one-time therapy has the distinction of being the most expensive drug in the world, with a price tag of $2.1 million. The FDA approved the drug from AveXis, Inc. on May 24 (SMA 7/1/19, p. 6). On June 28, AveXis — which was acquired by Novartis AG last year — notified the agency that there was “a data manipulation issue that impacts the accuracy of certain data from product testing performed in animals sub- mitted in the biologics license application (BLA) and reviewed by the FDA.” continued on p. 3 Report Reveals That Almost 100 RM/AT Products Are in Phase III Clinical Trials This past quarter saw two new gene therapies: Novartis AG subsidiary AveXis, Inc.’s Zolgensma (onasemnogene abeparvovec-xioi) received FDA approval May 24 for the treatment of spinal muscular atrophy (SMA 7/1/19, p.
  • Detection of Influenza a Viruses from Environmental Lake and Pond Ice

    Detection of Influenza a Viruses from Environmental Lake and Pond Ice

    TITLE “DETECTION OF INFLUENZA A VIRUSES FROM ENVIRONMENTAL LAKE AND POND ICE” Zeynep A. Koçer A Dissertation Submitted to the Graduate College of Bowling Green State University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY August 2010 Committee: Scott O. Rogers, Advisor W. Robert Midden Graduate Faculty Representative John Castello George Bullerjahn Paul Morris ii ABSTRACT Scott O. Rogers, Advisor Environmental ice is an ideal matrix for the long-term protection of organisms due to the limitation of degradative processes. As a result of global climate change, some glaciers and polar ice fields are melting at rapid rates. This process releases viable microorganisms that have been embedded in the ice, sometimes for millions of years. We propose that viral pathogens have adapted to being entrapped in ice, such that they are capable of infecting naïve hosts after melting from the ice. Temporal gene flow, which has been termed genome recycling (Rogers et al., 2004), may allow pathogens to infect large host populations rapidly. Accordingly, we hypothesize that viable influenza A virions are preserved in lake and pond ice. Our main objective was to identify influenza A (H1-H16) from the ice of a few lakes and ponds in Ohio that have high numbers of migratory and local waterfowl visiting the sites. We developed a set of hemagglutinin subtype-specific primers for use in four multiplex RT-PCR reactions. Model studies were developed by seeding environmental lake water samples in vitro with influenza A viruses and subjecting the seeded water to five freeze-thaw cycles at -20oC and -80oC.
  • Research Article Isolation of a Reassortant H1N2 Swine Flu Strain of Type (Swine-Human-Avian) and Its Genetic Variability Analysis

    Research Article Isolation of a Reassortant H1N2 Swine Flu Strain of Type (Swine-Human-Avian) and Its Genetic Variability Analysis

    Hindawi BioMed Research International Volume 2018, Article ID 1096079, 10 pages https://doi.org/10.1155/2018/1096079 Research Article Isolation of a Reassortant H1N2 Swine Flu Strain of Type (Swine-Human-Avian) and Its Genetic Variability Analysis Long-Bai Wang , Qiu-Yong Chen, Xue-Min Wu , Yong-Liang Che, Cheng-Yan Wang, Ru-Jing Chen, and Lun-Jiang Zhou Institute of Animal Husbandry and Veterinary Medicine, Fujian Academy of Agriculture Sciences, Fujian Animal Disease Control Technology Development Center, Fuzhou, Fujian 350013, China Correspondence should be addressed to Lun-Jiang Zhou; [email protected] Received 3 January 2018; Accepted 26 February 2018; Published 29 May 2018 Academic Editor: Jialiang Yang Copyright © 2018 Long-Bai Wang et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Weisolated an infuenza strain named A/Swine/Fujian/F1/2010 (H1N2) from a pig suspected to be infected with swine fu. Te results of electron microscopy, hemagglutination (HA) assay, hemagglutination inhibition (HI) assay, and whole genome sequencing analysis suggest that it was a reassortant virus of swine (H1N1 subtype), human (H3N2 subtype), and avian infuenza viruses. To further study the genetic evolution of A/Swine/Fujian/F1/2010 (H1N2), we cloned its whole genome fragments using RT-PCR and performed phylogenetic analysis on the eight genes. As a result, the nucleotide sequences of HA, NA, PB1, PA, PB2, NP, M, and NS gene are similar to those of A/Swine/Shanghai/1/2007(H1N2) with identity of 98.9%, 98.9%, 99.0%, 98.6%, 99.0%, 98.9%, 99.3%, and 99.3%, respectively.
  • Serological Methods in the Identification and Characterization of Viruses

    Serological Methods in the Identification and Characterization of Viruses

    CHAPTER 4 Serological Methods in the Identification and Characterization of Viruses M. H. V. Van Regenmortel Laboratoire de Virologie Institut de Biologie Mo!eculaire et Cellulaire 67000 Strasbourg, France 1. INTRODUCTION The purpose of this chapter is to present an integrated view of the various serological techniques that have been used in virology. The accent will be placed on the principles that govern each type of test and on the general applicability of the different serological techniques in all fields of virus research. In recent years, advances in serological tech­ niques have sometimes been applied in only one area of virology, although they could have been equally useful to workers studying other groups of viruses. No doubt this stems from the host-oriented approach that has guided the compartmentation of virology into separate fields of specialization. When it comes to serological properties, however, the similarities between animal, insect, bacterial, and plant viruses are paramount. The same immunochemical principles govern the in vitro serological reactions of all viral antigens, and much of general interest can be learned from the findings obtained with each particular group of viruses. An attempt will be made here to emphasize the general validity of specific experimental procedures. A number of recent reviews restricted to the serology of particular groups of viruses are available 183 H. Fraenkel-Conrat et al. (eds.), Comprehensive Virology © Plenum Press, New York 1981 184 Chapter 4 (Cowan, 1973; Schmidt and Lennette, 1973; Ball, 1974; Kurstak and Morisset, 1974; Burns and Allison, 1975; Mazzone and Tignor, 1976; Mayr et al., 1977; Tyrrell, 1978; Van Regenmortel, 1978; Cooper, 1979).
  • Curriculum Vitae

    Curriculum Vitae

    Curriculum Vitae PERSONAL INFORMATION Ulrike Schara WORK EXPERIENCE 1991- 1997 Education in Paediatrics Paediatric Outpatient Centre,City Hospital Gelsenkirchen. (Germany) Paediatric Outpatient Centre. City Hospital Gelsenkirchen.<br/>Childrens Hospital, Ruhr University Bochum<br/> 1998- 2002 Senior Neuropediatrics Children&apos;s University Hospital Bochum (Germany) . 2002- 2003 Head of Neuropediatrics Children&apos;s University Hospital Bochum (Germany) 2004- 2006 Head of Neuropediatrics Children&apos;s Hospital, City of Neuss (Germany) 2007- Present Head of the Neuropaediatric Outpatient Centre and Consultant for Neuropaediatrics University of Essen (Germany) EDUCATION AND TRAINING 1991- 2012 MD, Professor Ruhr University of Bochum, Germany University of Essen (Germany) ADDITIONAL INFORMATION Expertise Publications Publcations of the past 5 years 1.Rudnik-Schöneborn S, Tölle D, Senderek J, Eggermann K, Elbracht M, Kornak U, von der Hagen M, Kirschner J, Leube B, Müller-Felber W, Schara U, von Au K, Wieczorek D, Bußmann C, Zerres K. Diagnostic algorithms in Charcot-Marie-Tooth neuropathies: experiences from a German genetic laboratory on the basis of 1206 index patients. Clin Genet. 2016 Jan;89(1):34-43 2.Byrne S, Jansen L, U-King-Im JM, Siddiqui A, Lidov HG, Bodi I, Smith L, Mein R, Cullup T, Dionisi-Vici C, Al-Gazali L, Al-Owain M, Bruwer Z, Al Thihli K, El-Garhy R, Flanigan KM, Manickam K, Zmuda E, Banks W, Gershoni-Baruch R, Mandel H, Dagan E, Raas-Rothschild A, Barash H, Filloux F, Creel D, Harris M, Hamosh A, Kölker S, Ebrahimi-Fakhari D, Hoffmann GF, Manchester D, Boyer PJ, Manzur AY, Lourenco CM, Pilz DT, Kamath A, Prabhakar P, Rao VK, Rogers RC, Ryan MM, Brown NJ, McLean CA, Said E, Schara U, Stein A, Sewry C, Travan L, Wijburg FA, Zenker M, Mohammed S, Fanto M, Gautel M, Jungbluth H.
  • Innovationsreport 2020 Kurzfassung

    Innovationsreport 2020 Kurzfassung

    Innovationsreport 2020 Auswertungsergebnisse von Routinedaten der Techniker Krankenkasse aus den Jahren 2017 bis 2018 Herausgeber: Gerd Glaeske Erstellt mit freundlicher Unterstützung der Techniker Krankenkasse (TK) 3 Herausgeber Prof. Dr. Gerd Glaeske Experten für ausgewählte Kapitel Prof. Dr. med. Janbernd Kirschner, Bonn Prof. Dr. med. Dieter Ukena, Bremen Prof. Dr. med. Barbara Schmalfeldt, Hamburg Prof. Dr. med. Wolfgang Schramm, München Autoren Prof. Dr. med. Karl Broich, Dr. Stanislava Dicheva‐Radev, Dörte Fuchs, Prof. Dr. Gerd Glaeske, Dr. Marion Haberkamp, Dr. Iris Hinneburg, Friederike Höfel, Prof. Dr. Janbernd Kirschner, Dr. Wiebke Löbker, Anja Lübs, Dr. André S. Morawetz, Lutz Muth, Dr. Frauke Naumann‐Winter, Linda Richter, Saskia Ritter, Dr. Kristin Sauer, Dr. Birgit Schindler unter Mitarbeit von Esra Aksoy, Friederike Höfel, Berit Marquardt, Linda Richter, Marle Wilhelm Anschrift: Universität Bremen, SOCIUM, Mary‐Somerville‐Str. 5, 28359 Bremen Aus Gründen der besseren Lesbarkeit wurde auf die Nennung beider geschlechtsspezifischer Formen verzichtet. Im Allgemeinen ist aber das jeweils andere Geschlecht ebenfalls gemeint. 2 Glossar .......................................................................................... 7 Vorwort zum Innovationsreport 2020 ...........................................15 Vorwort des Herausgebers ............................................................17 1 Einleitung ................................................................................19 2 Ziele und Methodik..................................................................33
  • Zolgensma, INN-Onasemnogene Abeparvovec

    Zolgensma, INN-Onasemnogene Abeparvovec

    26 March 2020 EMA/200482/2020 Committee for Medicinal Products for Human Use (CHMP) Committee for Advanced Therapies (CAT) Assessment report Zolgensma International non-proprietary name: onasemnogene abeparvovec Procedure No. EMEA/H/C/004750/0000 Note The CAT Assessment report has been endorsed by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ...................................................................................... 6 1.2. Steps taken for the assessment of the product ......................................................... 9 2. Scientific discussion .............................................................................. 10 2.1. Problem statement ............................................................................................. 10 2.1.1. Disease or condition ......................................................................................... 10 2.1.2. Epidemiology .................................................................................................. 11 2.1.3.
  • Med Pharm PA List to Build Pdfs.Xlsx

    Med Pharm PA List to Build Pdfs.Xlsx

    The following medications, typically administered in a provider's office or ambulatory/outpatient infusion center, require authorization prior to utilization. Authorization requests can be submitted via the Portal. Additionally, you are welcome to call our member services line to initiate the Prior Authorization process. This list is updated quaterly. Effective date: 1/1/2021 Therapeutic category Brand Name Generic Name HCPCS Immunologic agent Orencia, IV infusion abatacept J0129 Botulinum toxins Dysport abobotulinumtoxin B J0586 HER-2 receptor drug Kadcyla ado-trastuzumab emtansine J9354 Ophthalmic injectable Eylea afilbercept J0178 Enzyme replacement drug Fabrazyme agalsidase beta J0180 Multiple sclerosis drug Lemtrada alemtuzumab J0202 Enzyme replacement drug Lumizyme alglucosidase alfa J0221 Enzyme replacement drug Strensiq asfotase alfa J3590 (non-specific) PD1-PDL1 drug Tecentriq atezolizumab J9022 PD1-PDL1 drug Bavencio avelumab J9023 CAR-T Therapy Yescarta axicabtageneciloleucel inpatient admin Systemic lupus erythematosus (SLE) drug Benlysta belimumab J0490 Antineoplastic agent Beleodaq belinostat J9032 Antineoplastic Belrapzo bendamustine HCl J9036 Antineoplastic Bendeka bendamustine HCl J9034 Antineoplastic agent Treanda bendamustine HCl J9033 Respiratory injectable Fasenra benralizumab J0517 J9035/J3590 (ophthalmology Antineoplastic Avastin bevacizumab uses this non-specific code) Antineoplastic agent Mvasi bevacizumab-awwb Q5107 Antineoplastic agent Zirabev bevacizumab-bvzr Q5118 Antineoplastic agent Blincyto blinatumomab
  • Virtual Posters

    Virtual Posters

    VIRTUAL POSTERS Poster # Title Primary Author First Name Primary Author Last Name City State Brain Tumors/OnCology 200 Clinical and Molecular Features of Atypical Pediatric Neurocytoma: A Case Series Adam Kalawi San Diego CA 201 Atypical molecular features of pediatric tectal glioma: A single institutional series Maayan Yakir San Diego CA 202 Hypercalcemia in Use of the Ketogenic Diet for Treatment of Spinal Lipoma Lila Worden Hartford CT Cognitive/Behavioral Disorders (inCluding Autism) 203 The neurodevelopmental profile of HIVEP2-related disorder Alisa Mo Boston MA 204 Burden of disease in a rare neurologic disorder: caregiver’s perspective on Aicardi Goutières Syndrome Francesco Gavazzi Philadelphia PA 205 Diagnosis delay in Aicardi Goutières Syndrome: a parents’ perspective Francesco Gavazzi Philadelphia PA 206 Validation of the telemedicine application of the Gross Motor Function Measure-88 Francesco Gavazzi Philadelphia PA 207 Altered Cerebellar White Matter in Sensory Processing Dysfunction Is Associated With Impaired Multisensory Integration and Attention Elysa Marco San Rafael CA 208 A comparison of the adaptive and autistic behavior in three developmental epileptic encephalopathies – SLC6A1, SCN2A, STXBP1 Kimberly Goodspeed Dallas TX 209 Spatial topography of cross-frequency coupling during NREM sleep is disrupted in Rett Syndrome Patrick Davis Boston MA 210 Serotonin transporter genotype predicts adaptive behavior outcomes in children with autism Kevin Shapiro Los Angeles CA 211 Clinical and Numerical presentation of Neurocognitive
  • Pharmacotherapy of Spinal Muscular Atrophy (SMA), 5.01.574

    Pharmacotherapy of Spinal Muscular Atrophy (SMA), 5.01.574

    PHARMACY / MEDICAL POLICY – 5.01.574 Pharmacotherapy of Spinal Muscular Atrophy (SMA) Effective Date: Nov. 1, 2020 RELATED MEDICAL POLICIES: Last Revised: Jan. 31, 2021 None Replaces: N/A Select a hyperlink below to be directed to that section. POLICY CRITERIA | DOCUMENTATION REQUIREMENTS | CODING RELATED INFORMATION | EVIDENCE REVIEW | REFERENCES | HISTORY ∞ Clicking this icon returns you to the hyperlinks menu above. Introduction Spinal muscular atrophy (SMA) is a rare disease that leads to muscle weakness and atrophy. SMA affects the muscles of the limbs and trunk. SMA is caused by changes to the survival motor neuron 1 gene (SMN1). This gene creates a protein called the survival motor neuron (SMN) protein. Too little of the SMN protein leads to muscle weakness that gets worse over time and muscles that waste away (atrophy). There are different types of SMA. Type 1 SMA, also known as Werdnig-Hoffman disease or infantile SMA, is the most severe form. Symptoms usually start before 6 months of age. The chance of survival to one year of age is 50 percent. Less severe forms are Type 2, also known as Dubowitz disease, and Type 3, or Kugelberg-Welander disease. Evrysdi™ (risdiplam), Spinraza® (nusinersen), and Zolgensma® (onasemnogene abeparvovec- xioi) are three treatments the Food and Drug Administration has approved for SMA. This policy discusses when the use of Evrysdi™, Spinraza®, and Zolgensma® may be considered medically necessary. Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals.
  • Generation of Influenza a Viruses Entirely from Cloned Cdnas

    Generation of Influenza a Viruses Entirely from Cloned Cdnas

    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 9345–9350, August 1999 Microbiology Generation of influenza A viruses entirely from cloned cDNAs GABRIELE NEUMANN*, TOKIKO WATANABE*†,HIROSHI ITO*, SHINJI WATANABE*†,HIDEO GOTO*, PENG GAO*, MARK HUGHES*, DANIEL R. PEREZ‡,RUBEN DONIS‡,ERICH HOFFMANN§,GERD HOBOM§, AND YOSHIHIRO KAWAOKA*¶ *Department of Pathobiological Sciences, School of Veterinary Medicine, University of Madison-Wisconsin, 2015 Linden Drive West, Madison, WI 53706; †Laboratory of Microbiology, Department of Disease Control, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan; ‡Department of Veterinary and Biomedical Sciences, University of Nebraska-Lincoln, P.O. Box 830905, Lincoln, NE 68583-0905; and §Institut fu¨r Mikro- und Molekularbiologie, Frankfurter Strasse 107, 35392 Giessen, Germany Communicated by Paul Ahlquist, University of Wisconsin, Madison, WI, May 27, 1999 (received for review March 23, 1999) ABSTRACT We describe a new reverse-genetics system ruses, which contain six (Thogotovirus), seven (influenza C that allows one to efficiently generate influenza A viruses virus), or eight (influenza A and B viruses) segments of entirely from cloned cDNAs. Human embryonic kidney cells negative-sense RNA, have been produced entirely from cloned (293T) were transfected with eight plasmids, each encoding a cDNAs. This lag in progress has been felt most acutely in viral RNA of the A͞WSN͞33 (H1N1) or A͞PR͞8͞34 (H1N1) efforts to control influenza virus infections. virus, flanked by the human RNA polymerase I promoter and Palese and colleagues (13) pioneered the reverse-genetics, the mouse RNA polymerase I terminator—together with plas- helper virus-dependent system for influenza A virus (Fig. 1A). mids encoding viral nucleoprotein and the PB2, PB1, and PA In their approach, a ribonucleoprotein (RNP) complex is viral polymerases.
  • Oligomerization of Bacterially Expressed H1N1 Recombinant

    Oligomerization of Bacterially Expressed H1N1 Recombinant

    www.nature.com/scientificreports OPEN Oligomerization of bacterially expressed H1N1 recombinant hemagglutinin contributes to Received: 30 April 2018 Accepted: 13 July 2018 protection against viral challenge Published: xx xx xxxx Tess E. Kuenstling1, Anthony R. Sambol1,2, Steven H. Hinrichs1,2 & Marilynn A. Larson1 Vaccination is the most efective intervention to prevent infuenza and control the spread of the virus. Alternatives are needed to the traditional egg-based vaccine strategy for a more rapid response to new outbreaks. Two diferent hemagglutinin (HA) fragments (rHA11-326 and rHA153-269) derived from infuenza A virus subtype H1N1 were expressed in Escherichia coli and characterized by immunoblot, gel fltration, hemagglutination, and competitive binding assays. rHA11-326 included neutralizing epitopes and the trimerization domain, whereas rHA153-269 included only the head of HA with the neutralizing epitopes. Mice were immunized with rHA11-326 or rHA153-269, and sera were tested for the presence of neutralizing antibodies. Mice were then challenged with H1N1 and infection severity was monitored. rHA11-326 trimerized, whereas rHA153-269 was unable to form oligomers. Both rHA11-326 and rHA153-269 elicited the production of neutralizing antibodies, but only oligomerized rHA11-326 protected against live virus challenges in mice. This study demonstrated that bacterially expressed HA was capable of folding properly and eliciting the production of neutralizing antibodies, and that HA oligomerization contributed to protection against viral challenge. Therefore, prokaryotic-derived vaccine platforms can provide antigenic and structural requirements for viral protection, as well as allow for the rapid and cost-efective incorporation of multiple antigens for broader protection. Infuenza seasonal infections lead to approximately 36,000 deaths in the United States alone each year with an associated annual economic burden of $87.1 billion dollars1,2.